Hedge Funds Snap Up Eli Lilly, United Healthcare, And More, Putting Healthcare ETFs Back In The Spotlight With funds buying Eli Lilly, UNH, and other pharma giants, healthcare ETFs can emerge as key beneficiaries of a broader defensive rotation.
Novo Nordisk Leans Into Affordability Amid Rising Competition Novo Nordisk offers limited-time $199 pricing on Wegovy and Ozempic, lowers self-pay costs, and prepares for a stronger Wegovy pill rollout.
Novo Nordisk's New Chair Aims To Reinforce Board As Foundation Tightens Control Novo Nordisk's new chair Lars Sorensen plans to add pharma expertise and address governance concerns after a major board overhaul backed by the company's foundation.
How Novo Nordisk Just Undercut Eli Lilly And The Trump Administration Novo Nordisk undercut Eli Lilly and the Trump administration on Monday, slashing the cash price of its Wegovy and Ozempic.
Novo Nordisk Offers WeGovy, Ozempic For $199 A Month As It Takes On Eli Lilly’s Zepbound The Danish drugmaker has announced that this offer is applicable to cash-paying patients looking to purchase introductory doses of Wegovy and Ozempic.
Deal Dispatch: Warner Bros., Bill.com, C3 AI—Key Auctions And Buyouts Shake The Market Paramount, Comcast, Netflix, Clearlake, Blackstone, and others drive major M&A activity. On the sell side are WBD, Bill.com and TuneIn.
Biopharma Boom: M&A Frenzy, AI Revolution, and GLP-1 Gold Rush Drive Robust Growth in 2025 The pharmaceutical and biotechnology sectors are experiencing a period of significant dynamism and robust growth as of November 2025, fueled by a confluence of scientific advancements, a resurgence in mergers and acquisitions (M&A), the transformative power of artificial intelligence (AI), and an evolving investor landscape. With the global biotechnology
Novo Nordisk Brings Back Former CEO To Lead Board Meanwhile, Cees de Jong was elected vice chair, replacing Henrik Poulsen, while Britt Meelby Jensen and Stephan Engels were appointed as members of the board at the meeting on Friday.
Why Did Scholar Rock Soar 26% Today? The company is planning to reapply for approval of a muscle atrophy therapy in the coming year.
Ozempic Maker Novo Nordisk Faces Board Shakeup Novo Nordisk faces board changes, investor friction and bold M&A moves as leadership pushes to regain momentum in the obesity drug market.
Is It Too Late to Buy Novo Nordisk After the Drop? Analysts still see 52% upside for Novo Nordisk -- find out whether its blockbuster drugs can spark a major rebound in 2025.
Why Is Everyone Talking About Novo Nordisk Stock? There is hardly a dull moment for the drugmaker these days.
Korro Bio Early Trial Results Fall Short; Stock Hits New Low Korro Bio shares drop after KRRO-110 trial in AATD misses protein goals; company cuts 34% of staff and shifts focus to liver-targeted programs.
Pfizer CEO Sees Metsera’s Drugs Hit Market As Early As 2028 After Completing Acquisition: Report CEO Albert Bourla told Yahoo Finance that the acquisition of GLP-1 maker Metsera is part of the company's "right to win" in the obesity drug game.
Pfizer Seeks To Exit BioNTech Investment After Lucrative Covid Vaccine Run Pfizer plans to sell its remaining BioNTech stake through a $508 million block trade, ending a profitable Covid-19 vaccine partnership.
Mangoceuticals Shares Soar Pre-market After Partnering with Eli Lilly, Novo Nordisk To Sell Obesity Drugs The company has launched two programs, MangoRx Direct and PeachesRx Direct, to provide access to Lilly’s Zepbound and Novo’s Wegovy medicines.
1 Incredible Reason to Buy LLY's Stock in November Eli Lilly struck a deal with President Donald Trump last week that could send the stock much higher.
Eli Lilly Soars: A Pharmaceutical Giant's Breakout Fueled by Blockbuster Drugs and Strategic Vision INDIANAPOLIS, IN – November 12, 2025 – Eli Lilly and Company (
NYSE: LLY ) is experiencing a monumental stock breakout today, sending ripples across the global financial markets. The pharmaceutical behemoth, already a dominant force, has seen its valuation surge on the back of sustained exceptional performance, breakthrough drug developments, and a pipeline
Novo Nordisk's $100 Million Coramitug Shows Promise In Reducing Heart Failure Biomarker Novo Nordisk's Coramitug cut NT-proBNP levels and was well tolerated in a Phase 2 ATTR-CM trial, paving the way for its Phase 3 CLEOPATTRA study.
